We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quark Pharmaceuticals Files Patent Application Covering Chemical Modifications to its RNAi Molecules
News

Quark Pharmaceuticals Files Patent Application Covering Chemical Modifications to its RNAi Molecules

Quark Pharmaceuticals Files Patent Application Covering Chemical Modifications to its RNAi Molecules
News

Quark Pharmaceuticals Files Patent Application Covering Chemical Modifications to its RNAi Molecules

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quark Pharmaceuticals Files Patent Application Covering Chemical Modifications to its RNAi Molecules"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quark Pharmaceuticals, Inc. announced that the Company has filed a patent application covering a number of chemical modifications that confer to the siRNA molecule stability and excellent penetration into the human cells tested.

"With the submission of this patent application, we believe we have provided significant additional protection for our pipeline program," said Daniel Zurr, President and CEO of Quark.

"Filing of this patent application marks a significant step in our efforts to solidify our position as a leader in the RNAi therapeutics space, as the new structures allow us more flexibility with regard to intellectual property. We believe our future siRNA therapeutics will be less dependent on in-licensed rights to RNAi technology. This patent application adds the element of structural design to our expertise in identifying clinically attractive drug targets using a proprietary discovery platform and local or systemic delivery."

The patent application relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop synthetic siRNA patterns with drug-like properties as well as improved targeted delivery systems.

Advertisement